EUCTR2004-002017-37-BE进行中（未招募）不适用
Phase III randomized trial of concomitant radiation, cisplatin, and tirapazamine (SR259075) versus concomitant radiation and cisplatin in patients with advanced head and neck cancer - TRACE
Sanofi-Synthelabo Research0 个研究点目标入组 550 人开始时间: 2006年1月24日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 550
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Previously untreated squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx
- •Stage III or IV disease (excluding T1N1, T2N1 and metastatic disease)
- •The disease must be considered to be potentially curable by combined chemoradiation
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Non adequate renal, hepatic or hematologic function
- •Significant intercurrent illness that will interfere with the chemotherapy or radiation therapy during the trial such as HIV infection, cardiac insufficiency, pulmonary compromise, active alcohol abuse, active infection or febrile illness
- •History of myocardial infarction, history of ventricular arrhythmias, angina or active coronary heart disease within 6 months, active peripheral claudication within 6 months
- •Primary cancers of the nasal and paranasal cavities and of the nasopharynx
- •Distant metastasis
- •Prior systemic chemotherapy for cancer
- •Prior radiation for head and neck cancer
- •Prior experimental therapy for cancer within 30 days of entering the trial
研究者
相似试验
进行中（未招募）
1 期
Phase III randomized trial of concomitant radiation, cisplatin, and tirapazamine (SR259075) versus concomitant radiation and cisplatin in patients with advanced head and neck cancer - TRACEEUCTR2004-002017-37-ESSanofi-Synthelabo Research550
进行中（未招募）
不适用
Phase III randomized trial of concomitant radiation, cisplatin, and tirapazamine (SR259075) versus concomitant radiation and cisplatin in patients with advanced head and neck cancer - TRACEEUCTR2004-002017-37-HUSanofi-Synthelabo Research550
进行中（未招募）
不适用
Phase III randomized trial of concomitant radiation, cisplatin, and tirapazamine (SR259075) versus concomitant radiation and cisplatin in patients with advanced head and neck cancer - TRACEOncology: Advanced Head and Neck cancerMedDRA version: 7.0Level: LLTClassification code 10025960EUCTR2004-002017-37-DESanofi-Synthelabo Research550
进行中（未招募）
不适用
Phase III randomized trial of concomitant radiation, cisplatin, and tirapazamine (SR259075) versus concomitant radiation and cisplatin in patients with advanced head and neck cancer.advanced head and neck cancerMedDRA version: 6.1Level: HLTClassification code 10024530EUCTR2004-002017-37-ITSANOFI-SYNTHELABO
进行中（未招募）
1 期
a research study to compare the standard treatment and the study drug (degarelix) in combination with radiotherapy in patients with high-risk localized or locally-advanced cancer, who receive this treatment after initial radical prostatectomy or as primary therapy.very high risk localized or locally advanced prostate cancerMedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-005098-19-GBEuropean Organisation for Research and Treatment of Cancer (EORTC)885